<DOC>
	<DOC>NCT00935844</DOC>
	<brief_summary>This study is being conducted to evaluate the safety profile and the Maximum Tolerated Dose (MTD) of TAK-901 in adult patients with advanced solid tumors or lymphoma. This study will help to identify the recommended phase 2 dose and infusion duration, and describe the pharmacokinetics of TAK-901.</brief_summary>
	<brief_title>Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Each patient must meet all of the following criteria to be enrolled in the study: ECOG performance status of &lt; or equal to 2. Diagnosis of solid tumor malignancy or lymphoma for which standard treatment is no longer effective. Have a radiographically or clinically evaluable tumor or lymphoma. Measurable disease as described in the protocol. Suitable venous access for the studyrequired blood sampling. Female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or abstain from heterosexual intercourse. Male patients who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse. Voluntary written consent. Weigh at least 45 kg. Recovered from the reversible effects of prior antineoplastic therapy. Meet clinical laboratory values during the screening period as specified in the protocol. Left ventricular ejection fraction (LVEF) &gt; or equal to 50% by echocardiogram or multiple acquisition scan (MUGA). Patients meeting any of the following exclusion criteria are not to be enrolled in the study: Diagnosis of primary CNS malignancy or carcinomatous meningitis. Patient has symptomatic brain metastasis. Prior bone allogeneic bone marrow or stem cell transplant. Prior radiotherapy involving &gt; or equal to 30% of the hematopoietically active bone marrow, within 21 days before the start of the study drug. Systemic antineoplastic therapy within 28 days before the start of the study drug, except for luteinizing hormonereleasinghormone (LHRH) agonist therapy. Exposure to nitrosureas or mitomycin C within 42 days before the start of the study drug. Treatment with monoclonal antibodies within 28 days before the start of the study drug. Known allergy or hypersensitivity to compounds of similar chemical composition to TAK901 or its excipient, Captisol. Female patients who are lactating or who have a positive serum pregnancy test during the screening period or a positive serum pregnancy test during the screening period. Myocardial infarction within 6 months before enrollment. Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure, angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Abnormalities on 12lead electrocardiogram (ECG) as specified in the protocol. Infection requiring systemic antiinfective therapy within 14 days before the start of study drug. Known human immunodeficiency virus (HIV)positive, hepatitis B surface antigenpositive status, or known or suspected active hepatitis C infection. Diagnosed or treated for another malignancy within 2 years before the start of study drug or previously diagnosed with another malignancy and have any evidence of residual disease. Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment. Treatment with any investigational products within 28 days before the first dose of study drug. Systemic use of strong CYP3A inhibitors or inducers (as specified in the protocol) within 14 days before the first dose of study drug.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Advanced solid tumors</keyword>
	<keyword>Lymphoma</keyword>
</DOC>